Orca Biosystems Inc.
BiotechOrca Biosystems Inc. is a biotechnology company focused on Oncology. Key products include tregzi.
Orca Biosystems Inc.'s Key Drugs
Orca Biosystems Inc.'s core commercial portfolio centers on tregzi, spanning Oncology — its most strategically important drugs approved in the last 15 years.
Orca Biosystems Inc.'s Recent FDA Approvals
Orca Biosystems Inc. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Orca Biosystems Inc.'s Therapeutic Areas
Orca Biosystems Inc.'s approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Orca Biosystems Inc.'s Top Competitors
Orca Biosystems Inc.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Orca Biosystems Inc. Pipeline Snapshot
Orca Biosystems Inc. has 4 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 1 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • tregzi leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2026-06-30
- Latest
- 2026-06-30
- Applications
- 1